Mandos is a biopharmaceutical company committed to furthering development of adrabetadex* for Niemann-Pick Type C. The company is led by a diverse and passionate management team experienced in every stage of the drug development process from research through commercialization.

Mandos attended the 2023 MICHAEL, MARCIA, AND CHRISTA PARSEGHIAN SCIENTIFIC CONFERENCE FOR NIEMANN-PICK TYPE C RESEARCH, June 10-13, Tucson, AZ

Please use this link to read the latest communications from Mandos, LLC.